<DOC>
	<DOCNO>NCT01743157</DOCNO>
	<brief_summary>A phase I-II study treatment metastatic melanoma use induction therapy Biochemotherapy plus Bevacizumab follow consolidation therapy Ipilimumab ( BBI ) .</brief_summary>
	<brief_title>Biochemotherapy Bevacizumab Followed Consolidation Therapy With Ipilimumab Metastatic Melanoma</brief_title>
	<detailed_description>A phase I-II study treatment metastatic melanoma use induction therapy Biochemotherapy ( Temodar , Cisplatin , Velban , IL2 IFN ) plus Bevacizumab follow consolidation therapy Ipilimumab ( BBI )</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Stage 4 unresectable stage 3 metastatic melanoma without measurable disease 2 . Age 1870 year old 3 . Adequate pulmonary cardiac function highdose IL2 4 . PS 02 5 . Previous ipilimumab therapy exclude patient , patient previous ipilimumab separate efficacy analysis 1 . Brain metastases 2 . Creatinine &gt; 2x ULN ; bilirubin &gt; 3 , WBC &lt; 3500 , Platelets &lt; 100,000 , Hgb &lt; 9 3 . Another active malignancy 4 . Gastrointestinal tract metastases except rectal metastasis primary allowable 5 . Previous therapy metastatic disease chemotherapy duration 3 month highdose interleukin2 6 . History colitis autoimmune disease lupus rheumatoid arthritis 7 . Bevacizumabrelated contraindication : Hemoptysis history severe bleeding , uncontrolled hypertension , proteinuria protein/creatinine ratio &gt; 1 , acute myocardial infarction within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>